Men are more prone to take risks for personal financial gain than women, and women are more likely than men to take risks to protect themselves from financial loss. Pexels

When motorcycle daredevil Evel Knievel leapt over cars, vans and fountains, it was little surprise that the person pulling those stunts was a man. That's not to say women never partake in high-risk behavior (Danica Patrick, anyone?). But decades of research confirm that men really are more inclined to take risks.

Snake River Canyon and the Indy 500 aside, economic life offers plenty of risks as well. When these risks involve investing, men under certain circumstances are more likely than women to take dangerous leaps, but why?

Rice Businesses professor Vikas Mittal joined Xin He of the University of Florida and J. Jeffrey Inman of the University of Pittsburgh in three studies to examine why men and women engage in risky business. Specifically, the team wanted to test whether each gender's risk-taking was moderated by a trait called issue capability: a decision-makers' belief that he or she can solve an issue.

The team grounded their work in agency-communion theory. This posits that men are more driven by goals that further self-interest ("agentic" goals) and women are more driven by goals that further coexistence ("communion" goals).

Based on this theory, the researchers hypothesized that men making investment decisions would take greater risks as their issue capability rose. This would occur because men, who are more focused on maximizing gains, would become more risk-seeking as their self-capability perceptions increased.

Conversely, the researchers theorized, women who faced similar investment decisions would focus on avoiding loss — even when their issue capability rose. This fundamental difference in investing perspective — men trying to maximize any gain versus women trying to minimize any loss – would be at the heart of a diametrically opposite stance on financial risk-taking.

All three studies proved the theory to be correct.

In the first study, the researchers asked men and women to wager money on Daily Double questions in "Jeopardy!" The male contestants with higher issue capability (i.e. demonstrated knowledge of the category) took the biggest risks. The women contestants showed equal levels of betting behavior regardless of whether they had high issue capability or not.

In the second study, the researchers dove into the psychology underlying gender and issue capability. First, the researchers primed male and female participants to believe they had either good or bad track records with risky investment decisions. Then they asked both groups to imagine they could invest $20,000 at varying levels of risk.

When it came to investing for gains, the researchers found, the women's beliefs about their issue capability made no real difference in their financial choices. Even after they had been primed to think they were highly capable investors, the women participants were less prone than the men to focus on the upside potential

And the men? Those who believed they were "capable" made the riskiest investment decisions. They also reported the highest number of thoughts about the positive potential of the various investment scenarios. Statistical analysis proved that these gain-maximization thoughts egged them on in their risk-taking.

On the other hand, those male participants who weren't primed to feel capable showed risk-taking patterns identical to that of the female participants. The results, in other words, suggest that the key difference between men and women's risk-taking is not innate — but stems from their self-conviction in investment competence.

The third study examined these processes in yet another way, by giving female and male participants the chance to maximize gains through making investments in stocks, or to minimize losses through buying insurance. Once again, the men primed to see themselves as ace investors made the riskiest investments. The women who felt themselves especially capable kept their risk-taking steady.

The women's behavior only changed when they thought they were subpar investors. When both women and men were told they were stock market duds, the women were more likely than the men to buy insurance — in other words, to take traditional measures to defend against loss.

Risk-taking choices, in other words, can no longer be written off as just boys being boys or girls being girls. More accurately, boys will be boys when a male investor thinks he is especially capable and that taking a risk will benefit him personally. That's not always a good thing. A female investor, who will typically focus on minimizing potential loss, can contribute a lot to investing decisions. Taking a big risk, as many an investor knows, isn't always the best move.

Mittal's findings inspire a list of possibilities for future research. What will happen to these behaviors as more women assume leadership jobs and more men get to show their skill as caregivers? Should senior management teams have both male and female representation to balance out the upsides and downsides of investment decisions? What about at home: would household decisions change for the better if both the man and the woman contributed their perspective?

------

This story originally ran on Rice Business Wisdom.

Vikas Mittal is the J. Hugh Liedtke Professor of Marketing at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.